28056901|t|Expansion of the Milan criteria without any sacrifice: combination of the Hangzhou criteria with the pre-transplant platelet -to- lymphocyte ratio
28056901|a|The Hangzhou criteria expand the Milan criteria safely and effectively in selecting hepatocellular carcinoma (HCC) candidates for liver transplantation (LT), but some patients exceeding the Milan but fulfilling the Hangzhou criteria still show poor outcomes due to early tumor recurrence. In this study, the platelet -to- lymphocyte ratio (PLR) was employed to differentiate high-risk tumor recurrence recipients, and a new method combining PLR and the Hangzhou criteria was established. The clinical data of 343 LT for HCC were retrospectively analyzed. Receiver operating characteristic (ROC) analysis was used to determine the PLR cut-off value to stratify patients exceeding the Milan but fulfilling the Hangzhou criteria. The recurrence-free survival (RFS) of recipients was compared after stratification. The Hangzhou criteria & PLR method was proposed and its feasibility was validated by ROC analysis. PLR 120 was the most significant cut-off value when comparing RFS of patients exceeding the Milan but fulfilling the Hangzhou criteria. After stratification, the 1-, 3-, and 5-year RFS of patients exceeding the Milan but fulfilling the Hangzhou criteria with PLR < 120 were 84.2%, 73.3%, and 73.3%, respectively, comparable with 85.7%, 73.9%, and 72.8%, respectively, in patients fulfilling the Milan criteria (P = 0.885). Patients exceeding the Milan but fulfilling the Hangzhou criteria with PLR ≥ 120 showed poor outcomes, which were similar in patients exceeding the Hangzhou criteria; 1-, 3-, and 5-year RFS were only 37.5%, 12.5%, and 12.5% vs. 32.3%, 17.6%, and 15.1%, respectively (P = 0.887). ROC analysis demonstrated that the ROC area of the Hangzhou criteria & PLR method was 0.768 for RFS. Multivariate analysis confirmed that PLR ≥ 120 was independently associated with RFS of patients exceeding the Milan but fulfilling the Hangzhou criteria. The Hangzhou criteria combined with the pre-transplant PLR can accurately exclude high-risk tumor recurrence recipients; this approach expands the Milan criteria effectively without any sacrifice.
28056901	0	9	Expansion	T082	UMLS:C0205229
28056901	17	31	Milan criteria	T170	UMLS:C0679228
28056901	74	91	Hangzhou criteria	T170	UMLS:C0679228
28056901	101	115	pre-transplant	T033	UMLS:C3841811
28056901	116	124	platelet	T017	UMLS:C0005821
28056901	130	140	lymphocyte	T017	UMLS:C0024264
28056901	151	168	Hangzhou criteria	T170	UMLS:C0679228
28056901	169	175	expand	T082	UMLS:C0205229
28056901	180	194	Milan criteria	T170	UMLS:C0679228
28056901	231	255	hepatocellular carcinoma	T038	UMLS:C2239176
28056901	257	260	HCC	T038	UMLS:C2239176
28056901	277	298	liver transplantation	T058	UMLS:C0023911
28056901	300	302	LT	T058	UMLS:C0023911
28056901	337	342	Milan	T170	UMLS:C0679228
28056901	362	379	Hangzhou criteria	T170	UMLS:C0679228
28056901	391	404	poor outcomes	T033	UMLS:C3806166
28056901	418	434	tumor recurrence	T038	UMLS:C0521158
28056901	455	463	platelet	T017	UMLS:C0005821
28056901	469	479	lymphocyte	T017	UMLS:C0024264
28056901	487	490	PLR	T058	UMLS:C0022885
28056901	522	531	high-risk	T033	UMLS:C0332167
28056901	532	548	tumor recurrence	T038	UMLS:C0521158
28056901	549	559	recipients	T098	UMLS:C1709854
28056901	588	591	PLR	T058	UMLS:C0022885
28056901	600	617	Hangzhou criteria	T170	UMLS:C0679228
28056901	639	652	clinical data	T170	UMLS:C1516606
28056901	660	662	LT	T058	UMLS:C0023911
28056901	667	670	HCC	T038	UMLS:C2239176
28056901	692	700	analyzed	T062	UMLS:C0936012
28056901	742	750	analysis	T062	UMLS:C0936012
28056901	777	780	PLR	T058	UMLS:C0022885
28056901	830	835	Milan	T170	UMLS:C0679228
28056901	855	872	Hangzhou criteria	T170	UMLS:C0679228
28056901	878	902	recurrence-free survival	T201	UMLS:C2919551
28056901	904	907	RFS	T201	UMLS:C2919551
28056901	912	922	recipients	T098	UMLS:C1709854
28056901	942	956	stratification	T062	UMLS:C1514983
28056901	962	979	Hangzhou criteria	T170	UMLS:C0679228
28056901	982	985	PLR	T058	UMLS:C0022885
28056901	1047	1055	analysis	T062	UMLS:C0936012
28056901	1057	1060	PLR	T058	UMLS:C0022885
28056901	1119	1122	RFS	T201	UMLS:C2919551
28056901	1149	1154	Milan	T170	UMLS:C0679228
28056901	1174	1191	Hangzhou criteria	T170	UMLS:C0679228
28056901	1199	1213	stratification	T062	UMLS:C1514983
28056901	1238	1241	RFS	T201	UMLS:C2919551
28056901	1268	1273	Milan	T170	UMLS:C0679228
28056901	1293	1310	Hangzhou criteria	T170	UMLS:C0679228
28056901	1316	1319	PLR	T058	UMLS:C0022885
28056901	1452	1466	Milan criteria	T170	UMLS:C0679228
28056901	1503	1508	Milan	T170	UMLS:C0679228
28056901	1528	1545	Hangzhou criteria	T170	UMLS:C0679228
28056901	1551	1554	PLR	T058	UMLS:C0022885
28056901	1568	1581	poor outcomes	T033	UMLS:C3806166
28056901	1628	1645	Hangzhou criteria	T170	UMLS:C0679228
28056901	1666	1669	RFS	T201	UMLS:C2919551
28056901	1763	1771	analysis	T062	UMLS:C0936012
28056901	1810	1827	Hangzhou criteria	T170	UMLS:C0679228
28056901	1830	1833	PLR	T058	UMLS:C0022885
28056901	1855	1858	RFS	T201	UMLS:C2919551
28056901	1897	1900	PLR	T058	UMLS:C0022885
28056901	1941	1944	RFS	T201	UMLS:C2919551
28056901	1971	1976	Milan	T170	UMLS:C0679228
28056901	1996	2013	Hangzhou criteria	T170	UMLS:C0679228
28056901	2019	2036	Hangzhou criteria	T170	UMLS:C0679228
28056901	2055	2069	pre-transplant	T033	UMLS:C3841811
28056901	2070	2073	PLR	T058	UMLS:C0022885
28056901	2097	2106	high-risk	T033	UMLS:C0332167
28056901	2107	2123	tumor recurrence	T038	UMLS:C0521158
28056901	2124	2134	recipients	T098	UMLS:C1709854
28056901	2162	2176	Milan criteria	T170	UMLS:C0679228